"Rituximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.
| Descriptor ID |
D000069283
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.075.785 D12.776.124.790.651.114.224.075.785 D12.776.377.715.548.114.224.284.785
|
| Concept/Terms |
Rituximab- Rituximab
- CD20 Antibody, Rituximab
- Rituximab CD20 Antibody
|
Below are MeSH descriptors whose meaning is more general than "Rituximab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.486.485.114.224.075]
- Rituximab [D12.776.124.486.485.114.224.075.785]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.790.651.114.224.075]
- Rituximab [D12.776.124.790.651.114.224.075.785]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.377.715.548.114.224.284]
- Rituximab [D12.776.377.715.548.114.224.284.785]
Below are MeSH descriptors whose meaning is more specific than "Rituximab".
This graph shows the total number of publications written about "Rituximab" by people in this website by year, and whether "Rituximab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 2 | 2 |
| 2009 | 0 | 8 | 8 |
| 2010 | 0 | 9 | 9 |
| 2011 | 0 | 4 | 4 |
| 2012 | 0 | 5 | 5 |
| 2013 | 0 | 5 | 5 |
| 2014 | 0 | 6 | 6 |
| 2015 | 0 | 3 | 3 |
| 2016 | 0 | 4 | 4 |
| 2017 | 2 | 2 | 4 |
| 2018 | 5 | 3 | 8 |
| 2019 | 3 | 0 | 3 |
| 2020 | 2 | 6 | 8 |
| 2021 | 0 | 5 | 5 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 5 | 5 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rituximab" by people in Profiles.
-
Trends in management of patients with new-onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis. Epilepsia. 2024 Aug; 65(8):e148-e155.
-
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024 04 18; 143(16):1616-1627.
-
Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2024 01 15; 209(2):137-152.
-
CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition. J Clin Oncol. 2024 Feb 01; 42(4):467-480.
-
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma. Ann Hematol. 2024 Jan; 103(1):185-198.
-
A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America. Blood Adv. 2023 09 26; 7(18):5202-5209.
-
Lupus mastitis and antiphospholipid syndrome treated with anticoagulation and immunosuppression: a case report. J Med Case Rep. 2023 Aug 09; 17(1):356.
-
Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study. Mult Scler Relat Disord. 2023 Jun; 74:104718.
-
Impact of electronic interventions on guideline concordant ordering of rituximab infusion rate. J Oncol Pharm Pract. 2022 Jul; 28(5):1157-1162.
-
Too much and not enough: revisiting maintenance rituximab in indolent lymphomas. Haematologica. 2022 02 01; 107(2):353-354.